Solid Tumors Harboring NTRK Fusion Clinical Trial
Official title:
A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer. The first study part (Phase 1) is done to determine what dose level of larotrectinib is safe for children, how the drug is absorbed and changed by their bodies and how well the cancer responds to the drug. The main purpose of the second study part (Phase 2) is to investigate how well and how long different cancer types respond to the treatment with larotrectininb.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02576431 -
A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
|
Phase 2 | |
| Completed |
NCT02122913 -
A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer
|
Phase 1 | |
| Completed |
NCT03215511 -
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
|
Phase 1 | |
| Completed |
NCT04275960 -
Study in Healthy Adult Male Participants to Gather Information How the Human Body Absorbs, Distributes and Excretes the Study Drug Selitrectinib Including the Effect of the Interaction of Food With the Study Drug on the Human Body
|
Phase 1 | |
| Completed |
NCT04771390 -
Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants
|
Phase 1 | |
| Completed |
NCT05192642 -
A Study Called VICTORIA to Learn More About How Well Larotrectinib Works in Adults With TRK Fusion-positive Cancer by Comparing Larotrectinib Data From Clinical Studies With Data of Other Treatments From Actual Practice
|
||
| No longer available |
NCT03206931 -
Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion
|